<DOC>
	<DOCNO>NCT01180634</DOCNO>
	<brief_summary>Patients cystic fibrosis ( CF ) suffer chronic infection low respiratory tract cause one multiple bacteria , include Pseudomonas aeruginosa , particularly problematic eradicate implicate major cause morbidity mortality CF patient . Aerosol delivery antibiotic directly lung increase local concentration antibiotic site infection result improve antimicrobial effect compare systemic administration . Decreased efficacy , intolerance high treatment burden currently available therapy indicate need additional therapy . MP-376 ( Aeroquin™ ) novel formulation fluoroquinolone levofloxacin optimize aerosol delivery . Preclinical clinical study conduct date show aerosol dose MP-376 safe well tolerate , exert antimicrobial effect , improve lung function reduce need anti-pseudomonal antibiotic . High concentration levofloxacin lung deliver MP-376 active CF pathogens include high minimum inhibitory concentration ( MIC ) level aminoglycosides tobramycin ( TOBI® ) inhale antimicrobial agent . Inhaled MP-376 deliver rapidly efficiently use customize PARI investigational configuration eFlow® nebulizer system .</brief_summary>
	<brief_title>MP-376 ( Aeroquin™ , Levofloxacin Inhalation ) Patients With Cystic Fibrosis</brief_title>
	<detailed_description>This trial double-blind , placebo-controlled study evaluate efficacy safety levofloxacin administer MP-376 give 28 day aerosol route CF patient .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Inclusion Criteria ( select ) : &gt; /= 12 year age Confirmed Diagnosis Cystic Fibrosis Positive sputum culture P. aeruginosa screen within past 12 month Patients able elicit FEV1 &gt; /= 25 % &lt; /= 85 % predict value screen Have receive least 3 course inhaled antimicrobial precede 12 month Clinically stable change health status within last 28 day Able reproducibly produce sputum perform spirometry Exclusion Criteria ( select ) : Use nebulized systemic antibiotic within 28 day prior baseline History hypersensitivity fluoroquinolones intolerance aerosol medication Evidence respiratory infection within 14 day prior dose CrCl &lt; 20ml/min &lt; 20ml/min/1.73 m2 Screening</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>